Heliyon (Mar 2023)
Administration of ketamine/xylazine increases severity of influenza (A/Puerto Rico/8/34) in mice
Abstract
The use of ketamine/xylazine for its anesthetic, anti-inflammatory, and anti-depressant properties could alter other medications and immune functions of the body. Thus, the current study explored how ketamine/xylazine affects the severity of influenza infection in BALB/c and C57Bl/6 mice, monitored for weight loss after intranasal inoculation with A/Puerto Rico/8/34 influenza virus. Mice were inoculated by using a micropipettor to insert 18 μL of control or a suspension of virus into each nostril and allowing the mouse to inhale the material. Several experiments were performed where groups of mice were treated with various combinations of virus and anesthesia and the results compared. Mice were weighed daily and monitored for other signs of illness. The experiments continued until the mice either regained their original weight or died (were euthanized when signs indicated non-recoverable status), which ranged from nine to twenty-three days. Anesthetized mice experienced more weight loss. Additionally, in experiments where the virus suspension was potent enough to lead to death, only mice that were anesthetized died.